万泰生物：子公司通过GMP符合性检查

Core Points - WanTai BioPharma's subsidiary, Xiamen WanTai Canghai Biotechnology Co., Ltd., passed the compliance inspection for Good Manufacturing Practice (GMP) [1] - The inspection covered the production workshop and production line for the nine-valent human papillomavirus (HPV) vaccine, conducted from November 5 to November 8, 2024, with a conclusion of compliance [1] - The nine-valent HPV vaccine is a self-developed biological product by the company, targeting seven high-risk types (HPV 16/18/31/33/45/52/58) and two low-risk types (HPV 6/11), aimed at preventing diseases related to HPV infections [1]